Patients with systolic heart failure and mild symptomatology [New York Heart Association class II] taking the mineralocorticoid receptor antagonist-eplerenone-experienced a 37% reduction in death from cardiovascular causes or first hospitalization for heart failure, researchers demonstrated in a new study.
Patients with systolic heart failure and mild symptomatology [New York Heart Association (NYHA) class II] taking the mineralocorticoid receptor antagonist-eplerenone-experienced a 37% reduction in death from cardiovascular causes or first hospitalization for heart failure, researchers demonstrated in a new study.
The study, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), was published on the New England Journal of Medicine website.
"Activation of the mineralocorticoid receptor by both aldosterone and cortisol plays an important role in the pathophysiology of heart failure, and mineralocorticoid receptors are overexpressed in the failing heart," noted researchers in their paper.
To test their hypothesis that the addition of a mineralocorticoid antagonist to current standard-of-care resulted in better outcomes in patients with mild heart failure, researchers randomly assigned 2,737 patients with NYHA class II heart failure and an ejection fraction ≤35% to receive eplerenone up to 50 mg daily or placebo, in addition to standard therapy (93% receiving an ACE inhibitor, ARB, or both; 87% a beta-blocker; 85% a diuretic; 26% digoxin; and 62% a lipid-lowering agent).
The trial was stopped prematurely, according to pre-specified rules, after a median follow-up of 21 months. The primary outcome of death from cardiovascular causes or first hospitalization for heart failure occurred less commonly in the eplerenone group (HR, 0.63; 95% CI, 0.54 to 0.74; P<.001). Moreover, fewer patients receiving eplerenone died for any reason (HR, 0.76; 95% CI, 0.62 to 0.93; P=.008) or due to cardiovascular causes (HR, 0.76; 95% CI, 0.61 to 0.94; P=.01). Hospitalizations for heart failure and for any cause were also reduced with eplerenone.
"The effect on death from cardiovascular causes or hospitalization for heart failure translates into an impressively low number needed to treat: 19 patients," noted Dr Paul W. Armstrong, MD, FRCP(C), from the University of Alberta in Edmonton, Canada, in an accompanying editorial. He continued, "The number needed to treat to prevent one death is 51 patients, positioning this therapy in the front rank of therapeutic choices."
However, eplerenone use was not without significant adverse effects. In particular, a serum potassium level >5.5 mmol/L occurred in 11.8% of patients in the eplerenone group compared to 7.2% in the placebo group (P<.001).
Approximately 5.8 million people in the United States have heart failure and about 670,000 Americans are diagnosed with it each year. Of these, 1 in 5 will die within 1 year from diagnosis.
SOURCES
Zannad F, McMurray JJV, Krum H; for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. DOI: 10.1056/NEJMoa1009492.
Armstrong PW. Aldosterone Antagonists - Last Man Standing? N Engl J Med. 2011. DOI:10.1056/NEJMe1012547.
American Heart Association. Heart Disease and Stroke Statistics – 2010 Update. Dallas, Texas: American Heart Association; 2010. Available at: http://www.americanheart.org/downloadable/heart/1265665152970DS-3241%20HeartStrokeUpdate_2010.pdf. Accessed November 15, 2010.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.